1. COVID‐19 breakthroughs: separating fact from fiction
   Paraminder Dhillon et al, 2020, FEBS J CrossRef
2. Development and progress of clinical trials of Coronavirus Disease 2019 antiviral drugs
   Wenyuan Pang et al, 2020, Expert Review of Clinical Pharmacology CrossRef
3. The Under-Reported Role of Toxic Substance Exposures in the COVID-19 Pandemic
   Ronald N. Kostoff et al, 2020, Food and Chemical Toxicology CrossRef
4. COVID-19 vaccines: ethical framework concerning human challenge studies
   Daniela Calina et al, 2020, DARU J Pharm Sci CrossRef
5. Azithromycin in the treatment of COVID-19: a review
   Daniel Echeverría-Esnal et al, 2020, Expert Review of Anti-infective Therapy CrossRef
6. The effect of antivirals on COVID-19: a systematic review
   Nafisa Hussain et al, 2020, Expert Review of Anti-infective Therapy CrossRef
7. The obesity paradox: Analysis from the SMAtteo COvid-19 REgistry (SMACORE) cohort
   Simona Biscarini et al, 2020, Nutrition, Metabolism and Cardiovascular Diseases CrossRef
8. Unraveling the Possible Routes of SARS-COV-2 Invasion into the Central Nervous System
   Maria Lima et al, 2020, Curr Treat Options Neurol CrossRef
9. SARS-CoV-2 pathophysiology and its clinical implications: An integrative overview of the pharmacotherapeutic management of COVID-19
   Aristides Tsatsakis et al, 2020, Food and Chemical Toxicology CrossRef
10. SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches—Insights into Chemical Structure—Biological Activity and Toxicological Screening
    Cristina Adriana Dehelean et al, 2020, JCM CrossRef
11. The bumpy road to achieve herd immunity in COVID-19
    Monica Neagu, 2020, Journal of Immunoassay and Immunochemistry CrossRef
12. Vaccine- and natural infection-induced mechanisms that could modulate vaccine safety
    Ronald N. Kostoff et al, 2020, Toxicology Reports CrossRef
13. Is Nanotechnology Helping in the Fight Against COVID-19?
    Valéria Maria de Oliveira Cardoso et al, 2020, Front. Nanotechnol. CrossRef
14. COVID ‐19: Topical agents and therapeutic prevention of nasal viral acquisition
    Shaden Abdelhadi et al, 2020, Dermatologic Therapy CrossRef
15. COVID-19 in health-care workers: lessons from SARS and MERS epidemics and perspectives for chemoprophylaxis and vaccines.
    Rémi Labetoulle et al, 2020, Expert Review of Vaccines CrossRef
16. A pharmacovigilance study to quantify the strength of association between the combination of antimalarial drugs and azithromycin and cardiac arrhythmias: implications for the treatment of COVID-19
    Vakaramoko Diaby et al, 2020, Expert Review of Pharmacoeconomics & Outcomes Research CrossRef
17. Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review
    Betsy Ann Joseph et al, 2020, Expert Review of Anti-infective Therapy CrossRef
18. Repositioning of Ligands That Target the Spike Glycoprotein as Potential Drugs for SARS-CoV-2 in an In Silico Study
    Gema Lizbeth Ramírez-Salinas et al, 2020, Molecules CrossRef
19. Improved strategies to counter the COVID-19 pandemic: Lockdowns vs. Primary and Community Healthcare
    Konstantinos Farsalinos et al, 2020, Toxicology Reports CrossRef
20. Emerging role of artificial intelligence in therapeutics for COVID-19: a systematic review
    Karanvir Kaushal et al, 2020, Journal of Biomolecular Structure and Dynamics CrossRef
21. Akt-Fas to Quell Aberrant T Cell Differentiation and Apoptosis in Covid-19
    Anthony J. Leonardi et al, 2020, Front. Immunol. CrossRef
22. Rationale for azithromycin in COVID-19: an overview of existing evidence
    Iwein Gyselinck et al, 2021, BMJ Open Resp Res CrossRef
23. Lung and Kidney ACE2 and TMPRSS2 in Renin-Angiotensin System Blocker–Treated Comorbid Diabetic Mice Mimicking Host Factors That Have Been Linked to Severe COVID-19
    Sri Nagarjun Batchu et al, 2021, Diabetes CrossRef
24. A dissection of SARS‑CoV2 with clinical implications (Review)
    Felician Stancioiu et al, 2020, Int J Mol Med CrossRef
25. COVID‐19: Risk Factors Associated with Infectivity and Severity
    Nahla Fadl et al, 2021, Scand J Immunol CrossRef
26. [Editorial] COVID‑19: Post‑lockdown guidelines
    Ronald Kostoff et al, 2020, Int J Mol Med CrossRef
27. Pan-India novel coronavirus SARS-CoV-2 genomics and global diversity analysis in spike protein
    Shweta Alai et al, 2021, Heliyon CrossRef
28. Inflammatory pathways and potential therapies for COVID-19: A mini review
    Areeg M Dabbish et al, 2021, Eur J Inflamm CrossRef
29. Oral Hsp90 Inhibitor, SNX-5422, Attenuates SARS-CoV-2 Replication and Dampens Inflammation in Airway Cells
    Ria Goswami et al, 2021, SSRN Journal CrossRef
30. Predicting COVID-19—Comorbidity Pathway Crosstalk-Based Targets and Drugs: Towards Personalized COVID-19 Management
    Debmalya Barh et al, 2021, Biomedicines CrossRef
31. Role of Serine Proteases and Host Cell Receptors Involved in Proteolytic Activation, Entry of SARS-CoV-2 and Its Current Therapeutic Options
    Gashaw Dessie et al, 2021, IDR CrossRef
32. New perspective towards therapeutic regimen against SARS-CoV-2 infection
    Vartika Srivastava et al, 2021, Journal of Infection and Public Health CrossRef
33. Could Histamine H1 Receptor Antagonists Be Used for Treating COVID-19?
    Changbo Qu et al, 2021, IJMS CrossRef
34. Triglyceride regulate ACE2 level through MTHFD1
    Xiaohua Ma et al, 2021, J Biosci CrossRef
35. Diagnosis, prevention, and treatment of coronavirus disease: a review
    Manoj Kumar Sarangi et al, 2021, Expert Review of Anti-infective Therapy CrossRef
36. Nanotechnology Integration for SARS-CoV-2 Diagnosis and Treatment: An Approach to Preventing Pandemic
    Syed Mohammed Basheeruddin Asdaq et al, 2021, Nanomaterials CrossRef
37. In silico drug repurposing in COVID-19: a network-based analysis
    Pasquale Sibilio et al, 2021, Biomedicine & Pharmacotherapy CrossRef
38. Nanobodies as powerful pulmonary targeted biotherapeutics against SARS-CoV-2, pharmaceutical point of view
    Ali Najmeddin et al, 2021, Biochimica et Biophysica Acta (BBA) - General Subjects CrossRef
39. Advances in the computational landscape for repurposed drugs against COVID-19
    Illya Aronskyy et al, 2021, Drug Discovery Today CrossRef
40. null
    Zacharenia Vlata et al, 2021 CrossRef
41. Antiviral strategies targeting host factors and mechanisms obliging +ssRNA viral pathogens
    Supreeti Mahajan et al, 2021, Bioorganic & Medicinal Chemistry CrossRef
42. Comparison of anti-SARS-CoV-2 activity and intracellular metabolism of remdesivir and its parent nucleoside
    Sijia Tao et al, 2021, Current Research in Pharmacology and Drug Discovery CrossRef
43. Drugs that Might Be Possibly Used for Treatment of COVID-19 Patients
    null Zahraa Talib Khudhair et al, 2021, Russ J Bioorg Chem CrossRef
44. In silico prediction of natural compounds as potential multi-target inhibitors of structural proteins of SARS-CoV-2
    Jyoti Rani et al, 2021, Journal of Biomolecular Structure and Dynamics CrossRef
45. Computationally repurposed drugs and natural products against RNA dependent RNA polymerase as potential COVID-19 therapies
    Sakshi Piplani et al, 2021, Mol Biomed CrossRef
46. Psychotropics and COVID-19: An analysis of safety and prophylaxis
    H. Javelot et al, 2021, L'Encéphale CrossRef
47. Patients affected by squamous cell carcinoma of the head and neck: A population particularly prone to developing severe forms of COVID‑19
    Francesco Perri et al, 2021, Exp Ther Med CrossRef
48. Combination therapies for COVID‐19: An overview of the clinical trials landscape
    Sola Akinbolade et al, 2021, Br J Clin Pharmacol CrossRef
49. Whey proteins and peptides in health-promoting functions – A review
    Changhui Zhao et al, 2021, International Dairy Journal CrossRef
50. null
    Subhendu Karmakar, 2022 CrossRef
51. Virtual Screening and In Silico Interactions Studies for Potential Antivirals and Diagnostics against the Spike protein from the Novel Coronavirus SARS-Cov-2
    F I Che Abd Aziz et al, 2021, IOP Conf. Ser.: Mater. Sci. Eng. CrossRef
52. Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection
    Mostafa Akbarzadeh-Khiavi et al, 2021, Infection CrossRef
53. Oral Hsp90 inhibitor SNX-5422 attenuates SARS-CoV-2 replication and dampens inflammation in airway cells
    Ria Goswami et al, 2021, iScience CrossRef
54. SARS-CoV-2 spreads through cell-to-cell transmission
    Cong Zeng et al, 2022, Proc Natl Acad Sci USA CrossRef
55. Lysine β-Hydroxybutyrylation Improves Stability of COVID-19 Antibody
    Zihua Li et al, 2021, Biomacromolecules CrossRef
56. In Silico Screening of Potential Phytocompounds from Several Herbs against SARS-CoV-2 Indian Delta Variant B.1.617.2 to Inhibit the Spike Glycoprotein Trimer
    Muruganantham Bharathi et al, 2022, Applied Sciences CrossRef
57. Potential therapeutic options for COVID-19: an update on current evidence
    Zahra Niknam et al, 2022, Eur J Med Res CrossRef
58. Ibuprofen, Flurbiprofen, Etoricoxib or Paracetamol Do Not Influence ACE2 Expression and Activity In Vitro or in Mice and Do Not Exacerbate In-Vitro SARS-CoV-2 Infection
    Natasja de Bruin et al, 2022, IJMS CrossRef
59. Treatment of patients with Covid‑19 with a high dose of ulinastatin
    Hai Huang et al, 2021, Exp Ther Med CrossRef
60. The Role of Nanotechnology in Antiviral Regime: An Overview
    Reena Singh et al, 2022, Nano LIFE CrossRef
61. Efficacy of the use of mefenamic acid combined with standard medical care vs. standard medical care alone for the treatment of COVID‑19: A randomized double‑blind placebo‑controlled trial
    Jose Guzman‑Esquivel et al, 2022, Int J Mol Med CrossRef
62. Possible effects of sirolimus treatment on the long‑term efficacy of COVID‑19 vaccination in patients with β‑thalassemia: A theoretical perspective
    Matteo Zurlo et al, 2022, Int J Mol Med CrossRef
63. The potential role of resveratrol as supportive antiviral in treating conditions such as COVID-19 – A formulator’s perspective
    Roy van Brummelen et al, 2022, Biomedicine & Pharmacotherapy CrossRef
64. SARS‑CoV‑2 infection and children: Insights from the 6th Workshop on Paediatric Virology (Review)
    Ioannis Mammas et al, 2022, World Acad Sci J CrossRef
65. Synthesis and Biological Evaluation of Umifenovir Analogues as Anti-SARS-CoV-2 Agents.
    Hiroaki Tanaka et al, 2022, ChemistrySelect CrossRef
66. Collective and individual rationality dilemma and the failure of anti-Covid-19 policies: Why some people don't wear masks?
    Farhad Nosrati Nejad et al, 2022, International Journal of Surgery CrossRef
67. Azithromycin use and outcomes in COVID-19 patients: an observational real-world study
    Ippazio Cosimo Antonazzo et al, 2022, International Journal of Infectious Diseases CrossRef
68. Lifestyle in Obese Individuals during the COVID-19 Pandemic
    Giovanna Pavone et al, 2022, Healthcare CrossRef
69. Analysis of Azithromycin adverse events in COVID-19 Patients reported to Iraqi Pharmacovigilance center in 2020
    null Yasir A. Noori et al, 2022, AJPS CrossRef
70. Neurovirulence of SARS CoV2: From Clinical Data to Preclinical Neuropsychological Exploration
    Youness Kadil et al, 2022, COVID CrossRef
71. Clinical characteristics and remission of nine cases with coronavirus disease 2019 infection in Zunyi, Southwest of China: A retrospective study
    Hongjun Chen et al, 2022 CrossRef
72. Establishment of multicenter COVID-19 therapeutics preclinical test system in Republic of Korea
    Hyuna Noh et al, 2023, Pulmonary Pharmacology & Therapeutics CrossRef
73. DRaW: prediction of COVID-19 antivirals by deep learning—an objection on using matrix factorization
    S. Morteza Hashemi et al, 2023, BMC Bioinformatics CrossRef
74. Effect of DPP4/CD26 expression on SARS‑CoV‑2 susceptibility, immune response, adenosine (derivatives m62A and CD) regulations on patients with cancer and healthy individuals
    Jiaman Du et al, 2023, Int J Oncol CrossRef
75. Microfluidic-based technologies for diagnosis, prevention, and treatment of COVID-19: recent advances and future directions
    E. Alperay Tarim et al, 2023, Biomed Microdevices CrossRef
76. null
    Priya Chauhan et al, 2023 CrossRef
77. Impact of Drug Repurposing on SARS-Cov-2 Main Protease
    Umar Ndagi et al, 2022, Russ. J. Phys. Chem. CrossRef
78. Noncovalent Nanoformulation of a Drug Candidate with Limited Systemic Delivery for Systemic Oral Delivery as Much as a Typical Common Oral Drug
    Chongkai Zhai et al, 2022, SSRN Journal CrossRef
79. null
    Taxiarchis Konstantinos Nikolouzakis et al, 2023 CrossRef
80. Oral delivery of a host-directed antiviral, niclosamide, as a cholate-coated nanoformulation
    Chongkai Zhai et al, 2023, International Journal of Antimicrobial Agents CrossRef
81. Mapping the Lipid Signatures in COVID-19 Infection: Diagnostic and Therapeutic Solutions
    Aishi Dasgupta et al, 2023, J. Med. Chem. CrossRef
82. Combined Use of Different Vaccine Models for Covid-19 And The Side-Effect Profile: A Single-Center Experience
    Ali AVCI et al, 2023, Turk J Int Med CrossRef
83. Nanotechnology-based theranostic and prophylactic approaches against SARS-CoV-2
    Atika Dhar et al, 2024, Immunol Res CrossRef
84. Analysis the Effectiveness of Remdesivir, Galidesivir, Sofosbuvir, Tenofovir and Ribavirin as Potential Therapeutic Drug target against SARS-Cov-2 RNA-Dependent RNA Polymerase (RdRp): An in Silico Docking Study
    Rajneesh Prajapat et al, 2023, Journal of Research in Applied and Basic Medical Sciences CrossRef
85. COVID-19: Characteristics and Therapeutics
    Rameswari Chilamakuri et al, 2021, Cells CrossRef
86. Phytochemicals in antiviral drug development against human respiratory viruses
    Surya Kant Mehta et al, 2024, Drug Discovery Today CrossRef
87. A Drug Repurposing Approach for Antimalarials Interfering with SARS-CoV-2 Spike Protein Receptor Binding Domain (RBD) and Human Angiotensin-Converting Enzyme 2 (ACE2).
    Paolo Coghi et al, 2021, Pharmaceuticals (Basel) CrossRef
88. Deciphering the Intricacies of Immune System Dysfunction and its Impact on Diabetes Mellitus: Revisiting the Communication Strategies to Manage Diabetes Mellitus
    null Vaibhav et al, 2024, Health Sciences Review CrossRef
89. COVID‑19: An update of current knowledge (Review)
    Vaishnavi Pandey et al, 2021, World Acad Sci J CrossRef
90. Systemic administration of human umbilical cord‑derived mesenchymal stem cells effectively ameliorates the outcomes of a critically ill elderly patient with COVID‑19 with multiple comorbidities: A case report
    Hongjun Chen et al, 2020, World Acad Sci J CrossRef
91. Psychological status of lung cancer patients and the effects of online intervention during the coronavirus disease 2019 pandemic
    Wenqi Sun et al, 2021, World Acad Sci J CrossRef
92. Probing the Action of Screened Anticancer Triazole–Tetrazole Derivatives Against COVID-19 Using Molecular Docking and DFT Investigations
    Rageh K. Hussein et al, 2022, Natural Product Communications CrossRef
93. Coronavirus disease‑2019 (Review)
    Ying Shu et al, 2021, World Acad Sci J CrossRef
94. Computational study of bioactive compounds from endophytic fungi against SARS-CoV-2
    Arpita Roy et al, 2023, Vegetos CrossRef